E1

68. (Amended). An isolated and purified nucleic acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5 and degenerate codon equivalents thereof.

Please delete claims 50-59 and 69 and add new claims 70-79 as follows:

Sub F3

70. (New). A method of detecting a presence of a target polynucleotide in a test sample, the method comprising the steps of:

(a) contacting a test sample with at least one reagent polynucleotide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, position 14-482 of SEQ ID NO:4, SEQ ID NO:5 and degenerate codon equivalents thereof; and

(b) detecting a presence of the target polynucleotide in the test sample.

E2

71. (New). The method of claim 70 wherein said target polynucleotide is attached to a solid phase prior to performing step (a).

Sub F4

72. (New). A method for detecting an amplicon in a test sample taken from a patient, the method comprising the steps of:

(a) obtaining a test sample from a patient;

(b) performing reverse transcription with at least one first primer in order to produce cDNA;

(c) amplifying the cDNA obtained from step (b) using sense and antisense primers to obtain an amplicon; and

(d) detecting a presence of the amplicon in a test sample,

Sub F4

wherein the primers utilized in steps (b) and (c) are selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, position 14-482 of SEQ ID NO:4, SEQ ID NO:5 and degenerate codon equivalents thereof.

73. (New). The method of claim 72, wherein the test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).

74. (New). The method of claim 72, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.

Sub F5
E 2

75. (New). A method of detecting a target polynucleotide in a test sample taken from a patient, the method comprising the steps of:

(a) obtaining a test sample from a patient;

(b) contacting the test sample with at least one first oligonucleotide as a sense primer and with at least one second oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product;

(c) contacting the first stage reaction product with at least one third oligonucleotide to obtain a second stage reaction product, with the proviso that the at least one third oligonucleotide is located 3' to the first and second oligonucleotides utilized in step (b) and is complementary to the first stage reaction product; and

(d) detecting the second stage reaction product as an indication of a presence of the target polynucleotide,

Sub F5

wherein the oligonucleotides utilized in steps (b) and (c) are selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, position 14-482 of SEQ ID NO:4, SEQ ID NO:5 and degenerate codon equivalents thereof.

76. (New). The method of claim 75 wherein the test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).

E2

77. (New). The method of claim 75 wherein the detecting step comprises utilizing a detectable label capable of generating a measurable signal.

78. (New). The method of claim 77 wherein the detectable label is reacted to a solid phase.

Sub F6

79. (New). A test kit comprising:

a container containing at least one polynucleotide encoding a mucin and selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, position 14-482 of SEQ ID NO:4, SEQ ID NO:5 and degenerate codon equivalents thereof.

REMARKS

Reconsideration and allowance of the above-referenced application are respectfully requested.

Claims 50-59 and 69 have been deleted and new claims 70-79 have been added. Claims 67 and 68 have been amended. No new matter has been added as a result of the amendment of claims 50-59 and 69 and the addition of new claims 70-79.